Immix Biopharma has successfully completed a stock offering, raising a total of $140.65 million. The funds generated from this offering are expected to support the company's ongoing research and development initiatives. This financial move reflects Immix Biopharma's strategic efforts to enhance its capital base and advance its business objectives in the biopharmaceutical sector.
Related Articles
Don't miss out on breaking stories and in-depth articles.